JMP Securities is very positive about IBIO and gave it a « » rating on Nov 29, 2021 . The price target was set to 0.85+29.15.
…
Predicted Opening Price for Ibio Inc of Monday, April 18, 2022.
| Fair opening price April 18, 2022 | Current price |
|---|---|
| $0.38 | $0.37 (Undervalued) |
Similarly, Is iBio a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank.
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
Who owns iBio stock? Top 10 Owners of Ibio Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| The Vanguard Group, Inc. | 4.75% | 10,357,682 |
| SSgA Funds Management, Inc. | 2.09% | 4,553,819 |
| Geode Capital Management LLC | 1.73% | 3,771,565 |
| Northern Trust Investments, Inc.(… | 0.87% | 1,901,858 |
Thereof, Why is iBio up?
Shares of iBio (NYSEMKT: IBIO) climbed on Friday after the biotech announced plans to develop an intriguing second-generation vaccine candidate for COVID-19. By targeting the N protein, iBio hopes to develop a vaccine that will be highly effective against new coronavirus variants.
Will iBio get government funding?
However, even with the nearly $12 million in aggregate cash recovery the company will receive as part of the resolution of its lawsuit with Fraunhofer USA, iBio is only funded until the end of March 2023.
How many employees does iBio have?
Company Description: Ibio, Inc. is located in Bryan, TX, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Ibio, Inc. has 75 total employees across all of its locations and generates $2.37 million in sales (USD).
…
Just $139.99 *
| Year | Revenue |
|---|---|
| 2020 | 1.64 |
| 2021 | 2.37 |
What does ibio company do?
Company Overview
iBio is leveraging its FastPharming Technologies to develop novel biopharmaceuticals for respiratory and fibrotic disease indications, among others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services.
What is ibio400?
[Available On-Demand] iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400).
Is iBio doing a reverse split?
The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote.
Is ibio doing a reverse split?
The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote.
Join TheMoney.co community and don’t forget to share this post !
